{
  "company": "LUPIN",
  "report_date": "August 13, 2024",
  "filename": "LUPIN_transcript_Aug_2024.pdf",
  "quarter": "Q1",
  "fiscal_year": "2025",
  "management_team": [
    "MS. VINITA GUPTA - CEO, LUPIN LIMITED",
    "MR. NILESH GUPTA - MANAGING DIRECTOR, LUPIN LIMITED",
    "MR. RAMESH SWAMINATHAN - EXECUTIVE DIRECTOR, GLOBAL CFO & HEAD OF API",
    "MR. RAVI AGRAWAL - M&A AND INVESTOR RELATIONS, LUPIN LIMITED",
    "VINITA GUPTA - CEO, LUPIN LIMITED",
    "NILESH GUPTA - MANAGING DIRECTOR, LUPIN LIMITED",
    "RAMESH SWAMINATHAN - EXECUTIVE DIRECTOR, GLOBAL CFO & HEAD OF API",
    "RAVI AGRAWAL - M&A AND INVESTOR RELATIONS, LUPIN LIMITED"
  ],
  "moderator": "Good evening and welcome to Lupin Limited Q1 FY25 Earnings Conference \nCall",
  "analysts": [],
  "qa_segments": [],
  "key_financial_metrics": {
    "sales_inr_crores": "5513",
    "growth_percentage": "8.7",
    "increase_percentage": "50",
    "ebitda_margin_percentage": "23.3",
    "ebitda_inr_crores": "1286"
  },
  "business_highlights": [
    "launched, additional new product launches like Pred- \nForteÂ® that we just received with CGT, Glucagon later in the fiscal year, \nLiposomal Doxorubicin that we're in the midst of launching at present, we \nexpect to grow our US business at a high single-digit in fiscal year '25.",
    "launched 28 products in FY24 and plan \nto launch around 20 products in FY25.",
    "launched product portfolio per se, which is sort \nof pulling your guidance at, let's say, high single digit growth for US business? \nVinita Gupta: \nYes, we are assuming that we'll have some erosion in Albuterol when \nAmphastar launches.",
    "partnerships with companies \nin place to really get access and gain share."
  ],
  "extraction_metadata": {
    "extraction_date": "2025-08-03T01:08:56.843870",
    "source_file": "data\\lupin\\LUPIN_transcript_Aug_2024.pdf",
    "text_length": 53988,
    "extraction_method": "PyMuPDF + Regex parsing + Filename analysis"
  }
}